Predictive Oncology Inc. (POAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
POAI Stock Summary
- The ratio of debt to operating expenses for PREDICTIVE ONCOLOGY INC is higher than it is for about only 4.95% of US stocks.
- POAI's price/sales ratio is 16.54; that's higher than the P/S ratio of 93.72% of US stocks.
- With a year-over-year growth in debt of -78.04%, PREDICTIVE ONCOLOGY INC's debt growth rate surpasses just 2.38% of about US stocks.
- Stocks that are quantitatively similar to POAI, based on their financial statements, market capitalization, and price volatility, are YCBD, SBT, TIG, MGLD, and GHSI.
- Visit POAI's SEC page to see the company's official filings. To visit the company's web site, go to www.predictive-oncology.com.
POAI Valuation Summary
- In comparison to the median Healthcare stock, POAI's price/sales ratio is 253.19% higher, now standing at 16.6.
- Over the past 157 months, POAI's price/sales ratio has gone down 245.9.
Below are key valuation metrics over time for POAI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| POAI | 2023-03-17 | 16.6 | 0.9 | -1 | -0.1 |
| POAI | 2023-03-16 | 16.4 | 0.9 | -1 | 0.0 |
| POAI | 2023-03-15 | 16.1 | 0.9 | -1 | 0.0 |
| POAI | 2023-03-14 | 15.9 | 0.9 | -1 | 0.0 |
| POAI | 2023-03-13 | 15.9 | 0.9 | -1 | 0.0 |
| POAI | 2023-03-10 | 15.1 | 0.8 | -1 | 0.0 |
POAI Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at -64.71%.
- The 4 year revenue growth rate now stands at 171.39%.
- Its 5 year net income to common stockholders growth rate is now at -267.51%.
The table below shows POAI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1.618479 | -12.87992 | -25.57803 |
| 2022-06-30 | 1.476315 | -13.10976 | -26.95657 |
| 2022-03-31 | 1.454931 | -11.98053 | -19.13918 |
| 2021-12-31 | 1.42068 | -12.20893 | -19.65717 |
| 2021-09-30 | 1.237975 | -10.76877 | -23.37064 |
| 2021-06-30 | 1.405069 | -11.06363 | -24.79463 |
POAI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- POAI has a Quality Grade of D, ranking ahead of 8.37% of graded US stocks.
- POAI's asset turnover comes in at 0.042 -- ranking 162nd of 186 Medical Equipment stocks.
- INO, EYES, and PETV are the stocks whose asset turnover ratios are most correlated with POAI.
The table below shows POAI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.042 | 0.637 | -7.254 |
| 2021-03-31 | 0.047 | 0.635 | -18.054 |
| 2020-12-31 | 0.055 | 0.643 | 58.433 |
| 2020-09-30 | 0.052 | 0.629 | 16.113 |
| 2020-06-30 | 0.050 | 0.616 | 9.041 |
| 2020-03-31 | 0.052 | 0.621 | 9.870 |
POAI Price Target
For more insight on analysts targets of POAI, see our POAI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
POAI Stock Price Chart Interactive Chart >
POAI Price/Volume Stats
| Current price | $0.34 | 52-week high | $1.10 |
| Prev. close | $0.33 | 52-week low | $0.21 |
| Day low | $0.32 | Volume | 391,470 |
| Day high | $0.36 | Avg. volume | 476,159 |
| 50-day MA | $0.43 | Dividend yield | N/A |
| 200-day MA | $0.39 | Market Cap | 27.15M |
Predictive Oncology Inc. (POAI) Company Bio
Predictive Oncology Inc. operates as a biotechnology company. The Company focuses focuses on applying data and artificial intelligence to personalized medicine and drug discovery. Predictive Oncology serves customers worldwide.
Latest POAI News From Around the Web
Below are the latest news stories about PREDICTIVE ONCOLOGY INC that investors may wish to consider to help them evaluate POAI as an investment opportunity.
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugsPredictive Oncology partners with the world's largest funder of cancer research to launch PEDAL(TM) Cancer Research Horizons to incorporate Predictive Oncology's PEDAL platform into future drug discovery processes to enable drug development on a global scale. EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK |
Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common StockEAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on March 27, 2023. The shares of Series F Preferred Stock will be distributed to such recipients a |
Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations PartnerComprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug developmentEAGAN, Minn., March 14, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility to acceler |
Predictive Oncology Issues Letter to ShareholdersSignature of Raymond F. Vennare, Chief Executive Officer Signature of Raymond F. Vennare, Chief Executive Officer EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to accelerate oncologic drug discovery and enable drug development, today issued the following letter to shareholders: Dear Shareholders and Stakeholders, As all of you know, on November 1, 2 |
Predictive Oncology partners with Cvergenx to create new genomics-based AI radiation therapyPredictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share news of their new partnership to develop the first-ever genomics-based approach to precis... |
POAI Price Returns
| 1-mo | -19.81% |
| 3-mo | -4.23% |
| 6-mo | -13.90% |
| 1-year | -68.22% |
| 3-year | -75.36% |
| 5-year | -96.96% |
| YTD | 10.89% |
| 2022 | -67.79% |
| 2021 | 29.97% |
| 2020 | -71.94% |
| 2019 | -57.90% |
| 2018 | -38.61% |
Loading social stream, please wait...